Addex Therapeutics Regains Compliance With NASDAQ's Minimum Bid Price Rule
Portfolio Pulse from Benzinga Newsdesk
Addex Therapeutics has regained compliance with NASDAQ's minimum bid price rule. The company's stock, ADXN, was previously at risk of being delisted due to its share price falling below the required minimum.

November 08, 2023 | 8:00 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Addex Therapeutics' stock, ADXN, has regained compliance with NASDAQ's minimum bid price rule, avoiding potential delisting.
Regaining compliance with NASDAQ's minimum bid price rule is a positive development for Addex Therapeutics. It removes the risk of delisting, which could have had a negative impact on the company's stock price. This news is likely to be viewed positively by investors, potentially leading to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100